PMID- 25645787
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20181202
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 47
IP  - 1
DP  - 2015 Jan-Feb
TI  - Induction therapy in simultaneous pancreas-kidney transplantation: thymoglobulin 
      versus basiliximab.
PG  - 120-2
LID - S0041-1345(14)01285-8 [pii]
LID - 10.1016/j.transproceed.2014.12.003 [doi]
AB  - BACKGROUND: Induction therapy for simultaneous pancreas-kidney (SPK) 
      transplantation. Both thymoglobulin (ATG) and basiliximab are the most-used types 
      of induction antibodies therapies in clinical practice. The aim of our report was 
      to analyze our experience comparing 2 induction therapies, for SPK 
      transplantation in terms of pancreas and patient survival, as well as rejection 
      rate. METHODS: We reviewed retrospectively a total of 97 SPK transplantations in 
      our institution. The cases were divided according to induction therapy in 2 
      groups, basiliximab (n = 38) and ATG (n = 59). Rejection, patient and graft 
      survival, and postoperative complications were analyzed. RESULTS: Survival in the 
      ATG group was better without statistical difference at 1-, 3-, and 5-year 
      follow-up (97%, 95%, and 95% versus 92%, 90%, and 87%, respectively). No 
      difference was detected in pancreas graft survival after 1-, 3-, and 5-year 
      follow-up (basiliximab 85%, 80%, and 77% versus ATG 84%, 84%, and 81%, 
      respectively; log-rank, 0.847). Overall cellular rejection and early rejection 
      were more common in the basiliximab group (30 versus 14%, and 21% versus 6%). In 
      the multivariate analysis considering human leukocyte antigen (HLA) mismatches, 
      the ATG group was a protective factor for cellular rejection. Major complications 
      (Grade III-IV) and median length of the hospital stay were higher in the 
      basiliximab group (55% versus 34%, P = .057, and 21 versus 16 days, P = .056). 
      CONCLUSIONS: The pancreas graft survival was not affected by induction therapy. 
      ATG induction therapy compared with basiliximab is associated with lower overall 
      and early rejection rate. Over time this difference disappears.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Fernandez-Burgos, I
AU  - Fernandez-Burgos I
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain. Electronic address: 
      isabel.fernandez.burgos@gmail.com.
FAU - Montiel Casado, M C
AU  - Montiel Casado MC
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Perez-Daga, J A
AU  - Perez-Daga JA
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Aranda-Narvaez, J M
AU  - Aranda-Narvaez JM
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Sanchez-Perez, B
AU  - Sanchez-Perez B
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Leon-Diaz, F J
AU  - Leon-Diaz FJ
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Cabello-Diaz, M
AU  - Cabello-Diaz M
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Rodriguez-Burgos, D
AU  - Rodriguez-Burgos D
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Hernandez-Marrero, D
AU  - Hernandez-Marrero D
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
FAU - Santoyo-Santoyo, J
AU  - Santoyo-Santoyo J
AD  - Department of Digestive Surgery and Transplantation, Hospital Regional 
      Universitario de Malaga, Malaga, Spain.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9927MT646M (Basiliximab)
RN  - D7RD81HE4W (thymoglobulin)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antilymphocyte Serum/*therapeutic use
MH  - Basiliximab
MH  - Female
MH  - Graft Rejection
MH  - Graft Survival
MH  - HLA Antigens/analysis
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Induction Chemotherapy/*methods
MH  - Kidney Transplantation/*mortality
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Pancreas Transplantation/*mortality
MH  - Postoperative Complications/epidemiology
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Retrospective Studies
EDAT- 2015/02/04 06:00
MHDA- 2015/10/31 06:00
CRDT- 2015/02/04 06:00
PHST- 2015/02/04 06:00 [entrez]
PHST- 2015/02/04 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
AID - S0041-1345(14)01285-8 [pii]
AID - 10.1016/j.transproceed.2014.12.003 [doi]
PST - ppublish
SO  - Transplant Proc. 2015 Jan-Feb;47(1):120-2. doi: 
      10.1016/j.transproceed.2014.12.003.